title: [New treatments for heart failure?].
abstract: Treatment of chronic heart failure still needs to be improved. Blockade of ET-1 and TNF-alpha, as well as the combined inhibition of ACE and NE have demonstrated limited benefits, thus other strategies continue being evaluated. This article reviews current concepts regarding the blockade of arginine vasopressin receptors (AVP) and the selective inhibition of matrix metalloproteinases (MMPs). Results with AVP blockade in humans have been encouraging, whereas inhibitors of MMPs continue under preclinical experimental phases and are controversial.
authors.affiliation: Clínica de Insuficiencia Cardíaca, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D.F.
authors.forename: Sergio
authors.initials: S
authors.lastname: Olvera Cruz
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D045726:Metalloproteases / Q000037:antagonists & inhibitors
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D045726:Metalloproteases
vernacular_title: Nuevas terapéuticas para la insuficiencia cardíaca?